DV
Dividend Vision

DMRA — Damora Therapeutics, Inc.

Damora Therapeutics, Inc. (DMRA)

Total return is -91.7% over the past 5.8 years, 246.2 points behind SPY at 154.5%. Its deepest 1-year drawdown was 72.4%.

Damora Therapeutics is a biopharmaceutical company developing therapies for hematologic disorders, including the investigational monoclonal antibody DMR-001 targeting CALR mutations for essential thrombocythemia treatment, additional anti-mutCALR therapies for myeloproliferative neoplasm patients, and GB3226, a small molecule inhibitor for acute myeloid leukemia. The company does not currently distribute dividends. Damora Therapeutics appeals to investors seeking exposure to early-stage biopharmaceutical development rather than income generation.

DMRA key facts

Asset type
Stock
Asset class
Equity
Inception date
10/29/2020
Last close
$31.04
Market cap
$1,937,694,464
Average volume
260700.0
Beta
1.467
Payout ratio
0.0
Forward P/E
0.0
EPS
$-2.68